SELLAS Life Sciences

Join us for a virtual R&D Day on Oct. 29 at 10am ET featuring KOLs, alongside company management, to discuss the unmet medical need and evolving treatment landscape for acute myeloid leukemia (AML). Register: lifescievents.com/event/g9avmapw…

At SELLAS Life Sciences, we’re focused on advancing novel, targeted cancer #immunotherapies with our clinically advanced #CancerVaccine platform and innovative CDK9 inhibitor programs across a broad range of cancer indications. Learn more about us here: bit.ly/3CqW8EJ

We are pleased to announce positive data from the Phase 2a trial of our highly selective CDK9 inhibitor in Diffuse Large B-Cell #Lymphoma. See how these results represent a promising step forward in improving outcomes for #DLBCL patients: bit.ly/4hMx22b

Following the positive outcome of our recent Ph3 interim analysis, we’re moving closer to offering a potentially transformative, well-tolerated treatment option for acute myeloid leukemia (#AML). See how we’re preparing for a BLA in this @OncLive article: bit.ly/4gpln85

#ICYMI: On Monday’s episode of the @WillCainShow_, our CEO, Dr. Angelos Stergiou, explores how #AI is revolutionizing cancer research & drug development. Watch to learn more and see how we’re at the forefront of innovation with our #CancerVaccine program: bit.ly/3WIQdSk

Today is #WorldCancerDay, an initiative led by @uicc to reduce the global impact of cancer. Join us in raising awareness as we work to contribute safe and effective cancer therapies with our potential first & best-in-class assets, GPS & SLS009. Learn more: bit.ly/2C4bCMA

Today at 12:15pm ET, our CEO, Dr. Angelous Stergiou, is going live on the @WillCainShow_ to discuss the role of #AICancerVaccines & targeted #immunotherapy in the fight against cancer. Tune in to see how we’re working to transform the future of healthcare: bit.ly/4hD8lF5

Our lead product candidate for acute myeloid leukemia (#AML) exceeded expectations in a recent Phase 3 interim analysis, demonstrating extended survival, a strong immune response, & no safety concerns. Learn more from this feature article in @CancerNetwrk: bit.ly/4glyJCf

#ICYMI, our President & CEO, Dr. Angelos Stergiou, was featured on @FoxBusiness’ The Big Money Show last Friday. Watch here for insights into the revolutionary impact of #AICancerVaccines & the work we’re doing to advance targeted cancer immunotherapies: bit.ly/4gfbslE

Tune into @FoxBusiness today at 1:50 p.m. ET to see our President & CEO, Dr. Angelos Stergiou, on The Big Money Show discussing the impact of #AICancerVaccines & how we’re advancing targeted immunotherapies for the treatment of cancer. For ways to watch: fxn.ws/3WvURCS

#ICYMI, our CEO, Angelos M. Stergiou, M.D., Sc.D. h.c., sat down with Brian Kilmeade of FOX & Friends at @foxnews to discuss the utilization & impact of AI cancer vaccines, offering insights into our clinically advanced #CancerVaccine platform. Watch here: foxnews.com/video/63675602…

We’re pleased to announce that our Phase 3 REGAL trial for acute myeloid #leukemia (#AML) has successfully passed the interim analysis for efficacy, futility and safety, and will continue without modification. Learn more here: bit.ly/40KpQh6

@SELLASLife is excited to share that our CCO, Robert Francomano, has been selected as the Chairperson for the upcoming “Chief Commercial Officer Summit” in Philadelphia, PA on October 4 – 5. View the agenda here: ow.ly/mShC50P3YAN

The lead indication for both of our clinical stage candidates is acute myeloid leukemia (#AML). Our mission is to prolong the lives of patients with AML. See an AML patient’s journey and the potential impact of our development programs below.

There are about 3,300 newly diagnosed malignant pleural mesothelioma cases in the US each year with rising incidence. Read about our Phase 1 MPM trial data which showed 70.3 weeks OS for patients treated with GPS in combination with Opdivo®: bit.ly/46j1LP

$SLS reports positive data in completed Phase 1 study of galinpepimut-S combined with Opdivo® in advanced mesothelioma. The primary safety endpoint and the efficacy endpoint were both met with clinical activity and increased survival observed. bit.ly/46j1LP8

“There will not be a magic day when we wake up and it’s now okay to express ourselves publicly. We make that day by doing things publicly until it’s simply the way things are.” – Tammy Baldwin, U.S. Senator. We wish all those celebrating a safe and happy weekend. #NYCPride

@SELLASLife announces that the first patient has been dosed in our Phase 2a clinical trial of CDK9 inhibitor, GFH009, in #AML. Topline data is expected during the fourth quarter of this year. Read more here: bit.ly/3Pnjyyz $SLS

DYK that in 2013 #CancerImmunotherapy was deemed “breakthrough of the year” by Science magazine? This form of cancer treatment has become standard of care for many different types of cancers. Learn more about our investigational immunotherapeutic, #GPS here: //bit.ly/3bTpkq4

Happy #PrideMonth2023 from #SELLASLifeSciences! This month, we celebrate the hard work and strength of the LGBTQ+ community while honoring each and every person’s expression of individuality in and out of the workplace. #LoveIsLove #PrideMonth